Pooja Shah

2PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Nov 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Angela K Green, Qin Zhou, Alexia Iasonos

Pageof 1